Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deprescribing Beta-Blockers in TTR Cardiac Amyloidosis
NCT05019027Phase 4Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of carvedilol in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Weill Cornell Medicine. Started Jan 2024; status: completed.
02
Drugs
carvedilol
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT05019027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019027.